<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Red Light Holland Corp — News on 6ix</title>
<link>https://6ix.com/company/red-light-holland-corp</link>
<description>Latest news and press releases for Red Light Holland Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/red-light-holland-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836840a78dffbe2df16985e.webp</url>
<title>Red Light Holland Corp</title>
<link>https://6ix.com/company/red-light-holland-corp</link>
</image>
<item>
<title>Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-completes-acquisition-of-filament-health-creating-a-global-leader-in-psychedelic-drug-development-commercialization-and-distribution</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-completes-acquisition-of-filament-health-creating-a-global-leader-in-psychedelic-drug-development-commercialization-and-distribution</guid>
<pubDate>Thu, 30 Apr 2026 11:30:00 GMT</pubDate>
<description>Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distributionAdds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologiesLeverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activitiesPositions the Company at the forefront of the rapidly emerging regulated psychedelic medicine industryAdvances clinical...</description>
</item>
<item>
<title>Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-announces-filament-health-obtains-final-order-for-proposed-arrangement</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-announces-filament-health-obtains-final-order-for-proposed-arrangement</guid>
<pubDate>Wed, 29 Apr 2026 11:30:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026, March 23, 2026 and April 27, 2026, that the Supreme Court of British Columbia has issued a final order (the "Final Order") approving the previously announced acquisition by Red Light of all the issued and...</description>
</item>
<item>
<title>Tripadvisor Announces 2026 Travelers' Choice Awards: Best of the Best Things to Do, Recognizing the World's Most Loved Travel Experiences and Attractions</title>
<link>https://6ix.com/company/red-light-holland-corp/news/tripadvisor-announces-2026-travelers-choice-awards-best-of-the-best-things-to-do-recognizing-the-worlds-most-loved-travel-experiences-and-attractions-1</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/tripadvisor-announces-2026-travelers-choice-awards-best-of-the-best-things-to-do-recognizing-the-worlds-most-loved-travel-experiences-and-attractions-1</guid>
<pubDate>Tue, 28 Apr 2026 04:01:00 GMT</pubDate>
<description>Tripadvisor Announces 2026 Travelers' Choice Awards: Best of the Best Things to Do, Recognizing t...</description>
</item>
<item>
<title>Red Light Holland Announces Filament Health Shareholder Approval of Acquisition</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-announces-filament-health-shareholder-approval-of-acquisition</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-announces-filament-health-shareholder-approval-of-acquisition</guid>
<pubDate>Mon, 27 Apr 2026 11:30:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026 and March 23, 2026, Filament's shareholders (the "Filament Shareholders") have approved each of the matters voted on at the Filament annual general and special meeting ("Filament Meeting") held on April 24, 2026, including...</description>
</item>
<item>
<title>Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-showcases-growing-clinical-demand-for-filament-healths-pex010-with-new-and-repeat-university-shipments</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-showcases-growing-clinical-demand-for-filament-healths-pex010-with-new-and-repeat-university-shipments</guid>
<pubDate>Fri, 24 Apr 2026 12:26:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions.Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including completed</description>
</item>
<item>
<title>Tripadvisor to Host First Quarter 2026 Financial Results Conference Call on May 7, 2026</title>
<link>https://6ix.com/company/red-light-holland-corp/news/tripadvisor-to-host-first-quarter-2026-financial-results-conference-call-on-may-7-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/tripadvisor-to-host-first-quarter-2026-financial-results-conference-call-on-may-7-2026-1</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>Tripadvisor to Host First Quarter 2026 Financial Results Conference Call on May 7, 2026 P...</description>
</item>
<item>
<title>Tripadvisor Summer Travel Index Shows East Coast and Florida Beaches as America's Most Sought-After Summer Destinations</title>
<link>https://6ix.com/company/red-light-holland-corp/news/tripadvisor-summer-travel-index-shows-east-coast-and-florida-beaches-as-americas-most-sought-after-summer-destinations-1</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/tripadvisor-summer-travel-index-shows-east-coast-and-florida-beaches-as-americas-most-sought-after-summer-destinations-1</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>Tripadvisor Summer Travel Index Shows East Coast and Florida Beaches as America's Most Sought-Aft...</description>
</item>
<item>
<title>Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-highlights-us-fda-authorized-study-supporting-multi-session-psilocybin-therapy-using-filament-healths-patented-pex010-botanical-drug-candidate</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-highlights-us-fda-authorized-study-supporting-multi-session-psilocybin-therapy-using-filament-healths-patented-pex010-botanical-drug-candidate</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of WashingtonSecond psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks69% of participants fell below clinical thresholds for anxiety and depression after second treatmentResearch builds on prior studies utilizing Filament's botanical psilocybin drug candidate, PEX010No serious adverse...</description>
</item>
<item>
<title>TCOM EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Trip.com Group (TCOM) Investors of Securities Class Action Deadline on May 11, 2026</title>
<link>https://6ix.com/company/red-light-holland-corp/news/tcom-equity-alert-faruqi-and-faruqi-llp-reminds-tripcom-group-tcom-investors-of-securities-class-action-deadline-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/tcom-equity-alert-faruqi-and-faruqi-llp-reminds-tripcom-group-tcom-investors-of-securities-class-action-deadline-on-may-11-2026</guid>
<pubDate>Thu, 09 Apr 2026 21:19:00 GMT</pubDate>
<description>Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Inves...</description>
</item>
<item>
<title>Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-reports-continued-expansion-of-filament-healths-pex010-clinical-network-with-new-license-agreements-and-research-shipments</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-reports-continued-expansion-of-filament-healths-pex010-clinical-network-with-new-license-agreements-and-research-shipments</guid>
<pubDate>Tue, 07 Apr 2026 11:30:00 GMT</pubDate>
<description>Three new license agreements signed and two research shipments completed in March 2026, spanning institutions in Australia, the United Kingdom, and CanadaToronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global clinical network for...</description>
</item>
<item>
<title>Tripadvisor Repays Convertible Senior Notes</title>
<link>https://6ix.com/company/red-light-holland-corp/news/tripadvisor-repays-convertible-senior-notes</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/tripadvisor-repays-convertible-senior-notes</guid>
<pubDate>Mon, 06 Apr 2026 20:05:00 GMT</pubDate>
<description>Tripadvisor Repays Convertible Senior Notes PR Newswire NEEDHAM, Mass. , April 6,...</description>
</item>
<item>
<title>Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-to-support-university-of-california-san-franciscos-global-psychedelic-study-through-filament-healths-clinical-network-6</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-to-support-university-of-california-san-franciscos-global-psychedelic-study-through-filament-healths-clinical-network-6</guid>
<pubDate>Wed, 01 Apr 2026 13:20:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the Carhart-Harris Lab ("CHL") at the University of California, San Francisco ("UCSF") by providing instructions on how to participate in the CHL Global Psychedelic Study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate use..</description>
</item>
<item>
<title>Tripadvisor and Starboard Value Enter into Cooperation Agreement</title>
<link>https://6ix.com/company/red-light-holland-corp/news/tripadvisor-and-starboard-value-enter-into-cooperation-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/tripadvisor-and-starboard-value-enter-into-cooperation-agreement</guid>
<pubDate>Mon, 23 Mar 2026 12:30:00 GMT</pubDate>
<description>Tripadvisor and Starboard Value Enter into Cooperation Agreement PR Newswire Two I...</description>
</item>
<item>
<title>Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-announces-filament-health-obtains-interim-order-for-proposed-arrangement</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-announces-filament-health-obtains-interim-order-for-proposed-arrangement</guid>
<pubDate>Mon, 23 Mar 2026 12:15:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to the joint press release dated March 10, 2026, the Supreme Court of British Columbia issued an interim order (the "Interim Order") in connection with the previously announced acquisition by Red Light of all the issued and outstanding common shares of Filament (the...</description>
</item>
<item>
<title>TCOM INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Trip.com Group (TCOM) Investors of Securities Class Action Deadline on May 11, 2026</title>
<link>https://6ix.com/company/red-light-holland-corp/news/tcom-investor-notice-faruqi-and-faruqi-llp-reminds-tripcom-group-tcom-investors-of-securities-class-action-deadline-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/tcom-investor-notice-faruqi-and-faruqi-llp-reminds-tripcom-group-tcom-investors-of-securities-class-action-deadline-on-may-11-2026</guid>
<pubDate>Fri, 20 Mar 2026 14:09:00 GMT</pubDate>
<description>Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Inves...</description>
</item>
<item>
<title>Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filaments-patented-pex010-botanical-psilocybin-drug-candidate</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filaments-patented-pex010-botanical-psilocybin-drug-candidate</guid>
<pubDate>Wed, 18 Mar 2026 13:00:00 GMT</pubDate>
<description>AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intell</description>
</item>
<item>
<title>Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filament-healths-patented-pex010-botanical-psilocybin-drug-candidate</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filament-healths-patented-pex010-botanical-psilocybin-drug-candidate</guid>
<pubDate>Wed, 18 Mar 2026 12:15:00 GMT</pubDate>
<description>AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industryToronto, Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's Researgency.ai agentic...</description>
</item>
<item>
<title>RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation</title>
<link>https://6ix.com/company/red-light-holland-corp/news/retransmission-red-light-holland-signs-definitive-agreement-with-filament-health-to-expand-its-platform-for-natural-psychedelic-drug-development-and-microdosing-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/retransmission-red-light-holland-signs-definitive-agreement-with-filament-health-to-expand-its-platform-for-natural-psychedelic-drug-development-and-microdosing-innovation</guid>
<pubDate>Wed, 11 Mar 2026 11:30:00 GMT</pubDate>
<description>Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulationCombines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidateAll-share transaction in which existing Red Light...</description>
</item>
<item>
<title>Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-signs-definitive-agreement-with-filament-health-to-expand-its-platform-for-natural-psychedelic-drug-development-and-microdosing-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-signs-definitive-agreement-with-filament-health-to-expand-its-platform-for-natural-psychedelic-drug-development-and-microdosing-innovation</guid>
<pubDate>Tue, 10 Mar 2026 20:40:00 GMT</pubDate>
<description>Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulationCombines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidateAll-share transaction in which existing Red Light...</description>
</item>
<item>
<title>Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update</title>
<link>https://6ix.com/company/red-light-holland-corp/news/red-light-holland-reports-third-quarter-2026-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/red-light-holland-corp/news/red-light-holland-reports-third-quarter-2026-results-and-provides-corporate-update</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and research and development ("R&D") initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences, which in parallel, operates commercial...</description>
</item>
</channel>
</rss>